ArticlePLoS neglected tropical diseases2025
Zika virus-specific and orthoflavivirus-cross-reactive IgGs correlate with Zika virus seroneutralization depending on prior dengue virus infection.
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Due to their expanding geographical distribution, many orthoflaviviruses co-circulate, increasing the likelihood of serial infections in individuals living in endemic areas. The consequences of such infection histories remain poorly understood. Using a cohort of Zika virus-infected patients, we modeled the kinetics of individual humoral responses to Zika virus (ZIKV) infection. We compared them between patients with and without prior orthoflavivirus exposure. We determined the day the humoral response was maximal and the maximum amplitude. We then determined the characteristic values of specific and cross-reactive responses for each individual, whether previously infected with dengue virus (DENV) or not. ZIKV neutralization by sera from ZIKV-infected individuals was mainly attributable to virus-specific antibodies. However, the same sera were able to neutralize all four DENV serotypes. ZIKV neutralization by sera from patients with prior DENV infection was mainly due to cross-reactive antibodies, which were also able to seroneutralize all four DENV serotypes. The de-novo antibody response induced against ZIKV was masked by the anamnestic response against DENV. Overall, our results show that the humoral response to an orthoflavivirus infection is influenced by the patient's history of prior orthologous orthoflavivirus infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.